SCM
NMTC icon

Stonepine Capital Management’s NeuroOne Medical Technologies NMTC Stock Holding History

Stonepine Capital Management’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-41,351
Closed -$273K – 29
2022
Q1 		$273K Sell
41,351
-41,708
-50% -$505K 0.11% 28
2021
Q4 		$967K Buy
+83,059
New +$1.34M 0.44% 21

Other funds holding NMTC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DWM
Drive Wealth Management Lehi, Utah $561M AUM 33.14% 1-Year Est. Return
KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
IC
Intersect Capital San Ramon, California $331M AUM 6.79% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Stonepine Capital Management's NMTC Position: Q2 2022 in Review

Stonepine Capital Management sold out of NeuroOne Medical Technologies (NMTC) in Q2 2022, closing a stake of 41,351 shares — an estimated $273K sold.

Stonepine Capital Management first reported a position in NMTC in Q4 2021 and held it in 2 quarters. The position peaked at $967K in Q4 2021. 10 funds tracked by Wall St. Rank hold NMTC as of Q2 2022.

  • Stonepine Capital Management reported no remaining NeuroOne Medical Technologies position as of Q2 2022 after selling out during the quarter.
  • Stonepine Capital Management sold 41,351 NeuroOne Medical Technologies shares in Q2 2022, an estimated $273K.
  • Stonepine Capital Management first reported a position in NeuroOne Medical Technologies in Q4 2021 and held it in 2 quarters.
  • Stonepine Capital Management's NeuroOne Medical Technologies position peaked at $967K in Q4 2021.
  • 10 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2022.

Based on Stonepine Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.